bs-9484R [Primary Antibody]
C5orf51 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: C5orf51

Immunogen Range: 1-100/294


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from human C5orf51

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

With 181 million base pairs encoding around 1,000 genes, chromosome 5 is about 6% of human genomic DNA. It is associated with Cockayne syndrome through the ERCC8 gene and familial adenomatous polyposis through the adenomatous polyposis coli (APC) tumor suppressor gene. Treacher Collins syndrome is also chromosome 5 associated and is caused by insertions or deletions within the TCOF1 gene. Deletion of the p arm of chromosome 5 leads to Cri du chat syndrome. Deletion of 5q or chromosome 5 altogether is common in therapy-related acute myelogenous leukemias and myelodysplastic syndrome. The LOC285636 gene product has been provisionally designated LOC285636 pending further characterization.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(WB=1:500-2000)
IHC-P(IHC-P=1:100-500)
IHC-F(IHC-F=1:100-500)
IF(IF=1:100-500)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Paraformaldehyde-fixed, paraffin embedded rat liver cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with C5orf51 Polyclonal Antibody, Unconjugated (bs-9484R) at 1:500 overnight at 4°C, followed by a conjugated secondary for 20 minutes and DAB staining.


LoVo cell lysates probed with C5orf51 Polyclonal Antibody, Unconjugated (bs-9484R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.